think you are perhaps not realizing that simply pointing to a self-replicating molecule that doesn't...
Thursday, May 29, 2008 news. This is information that was released, and known, years ago. Covered on...
by Jonathan Leininger through Rev. Dr. James Kenneth Powell II, opensourcebuddhism.org This piece ex...
An overview of the immune response This video is from: Janeway's Immunobiology, 7th Edition Murphy, ...
Your Science Your Say is an experimental project where three researchers 'pitch' their research via ...
PubMed |
(0) (0 Votes)
|
Views: (1) Date: (2005-8-27) Pages: () |
Abstract: In order to generate an immune response against myeloma cells in an homogenous murine model, a stable hybrid cell line (DCSp) was established through the syngenic fusion between mouse dendritic cells (DC) and mouse Sp2/0 myeloma cells. DCSp cells behaved as potent T cell stimulators and were able to induce Sp2/0 specific cytotoxicity. When mice were immunized with irradiated hybrids before SP2/0 injection, they exhibited a significantly higher rate of survival as compared with controls. When tumors were detected, their emergence was not delayed, and time elapsed between tumor clinical perception and death remained unchanged. A humoral immune response was also always associated. We assume that this stable dendritoma cell line can be considered a valuable tool for myeloma studies in an homogenous mouse model. The efficiency of dendritoma as a weapon against tumor cells and the benefit of syngeny in experimental models are discussed.